Effects of ketamine and midazolam on resting state connectivity and comparison with ENIGMA connectivity deficit patterns in schizophrenia
Bhim M. Adhikari, Juergen Dukart, Joerg F. Hipp, Anna Forsyth, Rebecca McMillan, Suresh Muthukumaraswamy, Meghann C. Ryan, L. Elliot Hong, Simon B. Eickhoff, Neda Jahandshad, Paul M. Thompson, Laura M. Rowland, Peter Kochunov
Human Brain Mapping October 21, 2019 DOI: 10.1002/hbm.24838 via OpenAlex
Summary
AI-generated from the abstractKetamine, given at subanesthetic doses to healthy volunteers, produces psychosis-like symptoms and reduces functional connectivity in the salience network, auditory network, and default mode network (DMN). Midazolam, a sedative, only reduces DMN connectivity. The pattern of connectivity deficits caused by ketamine positively correlates with the pattern seen in schizophrenia, whereas midazolam's effects do not. After subtracting midazolam's effects, the remaining ketamine-specific disconnectivity pattern still correlates with schizophrenia deficits. This suggests that ketamine's psychosis-like effects have a brain functional basis that overlaps with schizophrenia-related connectivity disruptions.
Study at a glance
| Characteristics | Randomized, three-way, cross-over study Peer reviewed |
|---|---|
| Sample size | 30 |
| Population | Healthy male volunteers aged 19–37 years |
| Interventions | Ketamine Midazolam Placebo |
| Dose | subanesthetic |
| Duration | Three imaging sessions with 48 hr between sessions; each session consisted of a control period followed by infusion |
| Topics | Ketamine |
| Keywords | Neuroscience Resting State FMRI Schizophrenia object-oriented programming Functional connectivity |
| Citations | 24 |
| Key finding | Ketamine-induced reductions in functional connectivity positively correlate with the pattern of connectivity deficits observed in schizophrenia. |
Abstract
Abstract Subanesthetic administration of ketamine is a pharmacological model to elicit positive and negative symptoms of psychosis in healthy volunteers. We used resting‐state pharmacological functional MRI (rsPhfMRI) to identify cerebral networks affected by ketamine and compared them to the functional connectivity (FC) in schizophrenia. Ketamine can produce sedation and we contrasted its effects with the effects of the anxiolytic drug midazolam. Thirty healthy male volunteers (age = 19–37 years) underwent a randomized, three‐way, cross‐over study consisting of three imaging sessions, with 48 hr between sessions. A session consisted of a control period followed by infusion of placebo or ketamine or midazolam. The ENIGMA rsfMRI pipeline was used to derive two long‐distance (seed‐based and dual‐regression) and one local (regional homogeneity, ReHo) FC measures. Ketamine induced significant reductions in the connectivity of the salience network (Cohen's d : 1.13 ± 0.28, p = 4.0 × 10 −3 ), auditory network ( d : 0.67 ± 0.26, p = .04) and default mode network (DMN, d : 0.63 ± 0.26, p = .05). Midazolam significantly reduced connectivity in the DMN ( d : 0.77 ± 0.27, p = .03). The effect sizes for ketamine for resting networks showed a positive correlation ( r = .59, p = .07) with the effect sizes for schizophrenia‐related deficits derived from ENIGMA's study of 261 patients and 327 controls. Effect sizes for midazolam were not correlated with the schizophrenia pattern ( r = −.17, p = .65). The subtraction of ketamine and midazolam patterns showed a significant positive correlation with the pattern of schizophrenia deficits ( r = .68, p = .03). RsPhfMRI reliably detected the shared and divergent pharmacological actions of ketamine and midazolam on cerebral networks. The pattern of disconnectivity produced by ketamine was positively correlated with the pattern of connectivity deficits observed in schizophrenia, suggesting a brain functional basis for previously poorly understood effects of the drug.